Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Opin Drug Discov. 2009 Jul;4(7):741-52. doi: 10.1517/17460440903002059. Epub 2009 Jun 9.

Preclinical development of cancer stem cell drugs.

Author information

1
Yale University, Department of Biomedical Engineering, New Haven, CT 06511, USA.

Abstract

BACKGROUND:

Despite recent progress in cancer treatment, the current cancer chemotherapy can mainly produce remission but often fails to cure cancer due to the existence of cancer stem cells. The emerging cancer stem cell hypothesis offers new insight into the failure of current cancer drugs and suggests new approaches for improved understanding of cancer biology and cancer drug development.

OBJECTIVE:

In this review, we discuss the concept of cancer stem cells, origin of cancer stem cells and different approaches for isolating or enriching cancer stem cells. We also review the resistance of cancer stem cells to standard chemotherapy and radiation therapy and potential mechanisms for the resistance. Finally, based on the current knowledge on cancer stem cells, we discuss potential approaches for developing new drugs that target cancer stem cells and propose new methods for evaluation of cancer stem cell drugs.

CONCLUSION:

Improved cancer treatment is likely to be achieved by a combination of drugs that kill both replicating cancer cells and more quiescent cancer stem cells.

PMID:
23489167
DOI:
10.1517/17460440903002059
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center